VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET.
NAMUR, Belgium, Aug. 8, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the second quarter ended June 30, 2016, it will host a conference call on Thursday, August 11, 2016, at 8:30 a.m. United States Eastern Time.
Cameron Reynolds, Chief Executive Officer, will host the call and provide an update on recent developments, including details of the ongoing clinical trials of the Company's NuQ® blood-based diagnostic platform. To participate in the call, please dial 1-800-946-0706 (toll-free) in the U.S. and Canada, and 1-719-325-2352 (toll) internationally. The conference ID number for both is 1996014. A live audio webcast of the conference call will also be available via link on the investor relations page of VolitionRx's corporate website at http://ir.volitionrx.com/.
After the live audio webcast, the event will remain archived on VolitionRx's website for one year. In addition, a telephone replay of the call will be available until August 25, 2016. The replay dial-in numbers are 1-877-870-5176 (toll-free) in the U.S. and Canada and 1-858-384-5517 (toll) internationally. Please use replay pin number 1996014.
VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
Visit VolitionRx's website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.
Media / Investor Contacts
Louise Day, VolitionRx
Scott Powell, VolitionRx
+44 (0)7557 774 620
+1 (646) 650-1351
Tirth Patel, Edison Advisors
Katherine Fennell, Edison Advisors
+1 (646) 653-7035
+44 (0) 20 7841 1556
Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-schedules-second-quarter-2016-earnings-conference-call-and-business-update-for-thursday-august-11-2016-at-830am-et-300309927.html
SOURCE VolitionRx Ltd